Pediatric Cancer Sequencing Expands Relapse Treatment Options in New Study
In a study of 774 children, 107 were successfully matched and treated with a molecularly targeted therapy differing from the standard of care.
SEngine Precision Medicine, Gustave Roussy to Offer Cancer Drug Sensitivity Testing in Europe
The partners aim to accelerate the implementation of precision oncology in the region, beginning with a clinical trial of colorectal and pancreatic cancer patients.
Metastatic Breast Cancer Genomes Point to Distinct Features, Tumor Evolution
With exome sequences from more than 600 metastatic breast tumors, researchers identified genomic alterations related to tumor progression, treatment response, and patient outcomes.
The launch of the sequencing platforms is a milestone for the Plan France Médecine Génomique 2025, a €670 million initiative the French government announced two years ago.
Protagen, Gustave Roussy Collaborating on Markers for Immunotherapy Side Effects
Under the collaboration, they will use Protagen's SeroTag platform to test cancer immunotherapy patients for markers linked to immune-related adverse events.